210 related articles for article (PubMed ID: 6751209)
1. Immunological aspects of experimental brain tumors (review).
Stavrou D; Bilzer T; Hultén M; Zänker KS; Anzil AP; Haglid KG; Dahme E
Anticancer Res; 1982; 2(3):151-5. PubMed ID: 6751209
[TBL] [Abstract][Full Text] [Related]
2. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.
Gately MK; Glaser M; Dick SJ; Mettetal RW; Kornblith PL
J Natl Cancer Inst; 1982 Dec; 69(6):1245-54. PubMed ID: 6183477
[TBL] [Abstract][Full Text] [Related]
3. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
4. Tumor markers of the central nervous system.
Birkmayer GD
Cancer Detect Prev; 1981; 4(1-4):231-8. PubMed ID: 7349780
[TBL] [Abstract][Full Text] [Related]
5. Immunological reactions to gliomas.
Ridley A
Mod Trends Neurol; 1975; 6():249-66. PubMed ID: 1105142
[No Abstract] [Full Text] [Related]
6. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
7. [Immunologic sensitization to tumor-associated antigens during the growth of gliomas of the brain (experimental study)].
Novichenko NL; Romodanov AP; Zhmareva EN; Gorovoĭ AI
Zh Vopr Neirokhir Im N N Burdenko; 1984; (2):9-13. PubMed ID: 6741378
[TBL] [Abstract][Full Text] [Related]
8. Derivation of a brain tumor-selective monoclonal antibody from hybridoma between mouse myeloma and rat spleen cells immune to syngeneic glioma.
Saya H; Masuko T; Hashimoto Y
Jpn J Cancer Res; 1985 Dec; 76(12):1198-202. PubMed ID: 3937832
[TBL] [Abstract][Full Text] [Related]
9. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
11. Proceedings: Immunological investigations on human brain tumor patients.
Mahaley MS
Proc Natl Cancer Conf; 1972; 7():811-5. PubMed ID: 4358071
[No Abstract] [Full Text] [Related]
12. The influence of various chemicals on the surface structure and the antigenicity of syngeneic glioma cells.
Zänker KS; Stavrou D; Hultén M; Bilzer T
Anticancer Res; 1981; 1(2):101-7. PubMed ID: 7347153
[TBL] [Abstract][Full Text] [Related]
13. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
14. [Effects of adult thymectomy on the growth of 203-glioma in mice--analysis of T cell subpopulation in tumor immunology].
Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
No To Shinkei; 1982 Nov; 34(11):1067-75. PubMed ID: 6984337
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack.
Gately CL; Muul LM; Greenwood MA; Papazoglou S; Dick SJ; Kornblith PL; Smith BH; Gately MK
J Immunol; 1984 Dec; 133(6):3387-95. PubMed ID: 6238097
[TBL] [Abstract][Full Text] [Related]
16. [Partial characterization of surface tumor associated antigens of established murine glioma cell line (203-glioma) (author's transl)].
Nakao S
No To Shinkei; 1979 Jan; 31(1):95-103. PubMed ID: 426937
[No Abstract] [Full Text] [Related]
17. Surface antigens of human glioma cells shared with normal adult and fetal brain.
Wikstrand CJ; Bigner DD
Cancer Res; 1979 Aug; 39(8):3235-43. PubMed ID: 88260
[No Abstract] [Full Text] [Related]
18. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers of the central nervous system: biological basis and clinical relevance.
Birkmayer GD
Cancer Detect Prev; 1983; 6(1-2):317-24. PubMed ID: 6883389
[TBL] [Abstract][Full Text] [Related]
20. Cell-mediated immune response in rats immunized with chemically modified syngeneic glioma cells. Monitoring by in vivo parameters and in vitro immune cytolysis.
Bilzer T; Stavrou D; Dahme E; Anzil AP
Anticancer Res; 1982; 2(6):345-54. PubMed ID: 6984814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
